250 related articles for article (PubMed ID: 24895877)
1. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
2. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
[TBL] [Abstract][Full Text] [Related]
3. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
4. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
5. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.
Kusakabe K; Yokoyama K; Ito K; Shibuya H; Kinuya S; Ito M; Higashi T; Togawa T; Koizumi K; Yoshimura M; Uchiyama M; Okamoto T; Kanaya S; Kanaya K; Yoneyama T; Ikebuchi H; Yanagida S; Shibata K; Segawa K; Yamamoto A
Ann Nucl Med; 2012 May; 26(4):370-8. PubMed ID: 22450825
[TBL] [Abstract][Full Text] [Related]
6. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
[TBL] [Abstract][Full Text] [Related]
7. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
Barrington SF; Kettle AG; O'Doherty MJ; Wells CP; Somer EJ; Coakley AJ
Eur J Nucl Med; 1996 Feb; 23(2):123-30. PubMed ID: 8925845
[TBL] [Abstract][Full Text] [Related]
8. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
Coover LR; Silberstein EB; Kuhn PJ; Graves MW
J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
[TBL] [Abstract][Full Text] [Related]
10. Thyroid remnant ablation with 1110MBq of 131I in outpatients: measurement of effective dose to household members and establishment of safety precautions.
Yoshimura M; Tsutsui H; Ikeda N; Koizumi K
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):101-8. PubMed ID: 23474638
[TBL] [Abstract][Full Text] [Related]
11. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.
Liu B; Kuang A; Huang R; Zhao Z; Zeng Y; Wang J; Tian R
J Nucl Med; 2010 Apr; 51(4):618-23. PubMed ID: 20237029
[TBL] [Abstract][Full Text] [Related]
12. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
13. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
14. 131I effective half-life and dosimetry in thyroid cancer patients.
Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
Huić D; Medvedec M; Dodig D; Popović S; Ivancević D; Pavlinovic Z; Zuvic M
Nucl Med Commun; 1996 Oct; 17(10):839-42. PubMed ID: 8951903
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
[TBL] [Abstract][Full Text] [Related]
17. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
[TBL] [Abstract][Full Text] [Related]
18. Potential third-party radiation exposure from patients undergoing therapy with 131I for thyroid cancer or metastases.
D'Alessio D; Giliberti C; Benassi M; Strigari L
Health Phys; 2015 Mar; 108(3):319-25. PubMed ID: 25627943
[TBL] [Abstract][Full Text] [Related]
19. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.
Gabriel S; Farman-Ara B; Bourrelly M; Carpentier O; Sebag F; Palazzo FF; De Micco C; Mancini J; Henry JF; Mundler O; Taïeb D
Nucl Med Commun; 2011 Sep; 32(9):829-33. PubMed ID: 21633315
[TBL] [Abstract][Full Text] [Related]
20. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
